'I was in awe of how committed Kareena was, even at this stage of her career.' 'She is so motivated, giving it her all. 'It was very inspiring and motivating, not just for me, but for everyone else to pull up their socks and give it their all.'
The challenge of merging Ranbaxy into the company has not been factored in.
Free Basics offers a limited version of the Internet on mobile phones.
The founders of Gland Pharma, led by Ravi Penmetsa, and KKR, together own 96 per cent of the company.
What sold the most this year? Beauty, toys and baby care, sports and fitness, television and large appliances, followed by fashion, says T E Narasimhan.
Basic Customs Duty is being reduced to 2.5 per cent for the equipments required for setting up or substantial expansion of iron ore pellet plants & iron ore beneficiation plants.
DRL launched four new products in North America during the previous quarter.
The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.
Global companies, e-commerce platforms and software product firms all want skilled digital workers.
Mylan had sued the United States Food and Drugs Administration for providing the exclusive right to Ranbaxy, alleging the permission was given on the basis of 'falsified data'.
Rs 1,965-cr deal helps it rake in 3.5 times its investment within four years.
Netmeds is looking at using new technologies such as deep learning and data analytics to improve forecasting in terms of the demand of the products for pharma companies, reports Peerzada Abrar.
The order, a "negative" overall, will be a short term positive for corporate focused state-run and private lenders because of the possibility of delaying incremental stressed asset recognition.
By the time the film winds down in extremely simplistic fashion, we just don't care anymore.
The government on Monday said that multinational companies (MNCs) are campaigning against domestic pharmaceuticals industry as their interests were getting impacted due to increasing global presence of Indian firms in the generic segment.
India could offer a train track to China to run a bullet train besides easy terms to set up industrial parks.
US said access to affordable health care entails a large number of factors from rates, logistics to insurance reforms.
India has a huge trade surplus with US - over $20 billion a year in the past five years.
Indian pharmaceutical companies, which always wanted a big share in the global copycat drug market, are betting high on the oral contraceptive (OC) market in America.
Dr Reddy's Laboratories today said it will form a joint venture with Fujifilm Corporation to develop, manufacture and market generic drugs in Japan.
The Internet Corporation of Assigned Names and Numbers' (ICANN) decision to expand gTLD (generic top-level domain) names on the internet to include almost any name (even .anything), is foxing both users and registers. It has also raised fears of online trademark violations and cybersquatting.
European countries are trying to woo back the Indian customers they had lost following seizure of drug consignments by Customs authorities of several European Union members.
'The focus for value creation will be on all business segments.'
'It is clear that economic policy and reform under this administration will always be afterthoughts, something to be carried out only when no other political concern intervenes -- when, in other words, the government feels safe and comfortable enough to take a moderate risk,' argues Mihir S Sharma.
Trade analyst Vinod Mirani gives us the box office verdict for the week.
Changing your body type may seem to be difficult, but you can still manage to get it in great shape. You can be the architect of your own body with these eight simple steps!
The pact would entail the Indian company receiving up to $38 million (over Rs 165 crore).
Respiratory product paves way for launch in larger markets and greater earnings visibility.
Antacid Digene and pain drug Brufen have been among the top in their categories in India for decades. But not their manufacturer, Abbott.
Ranbaxy's hope of a windfall from the $7-billion Lipitor market in the US is shining again. The US Food and Drugs Administration (USFDA) has taken a strong stance against US-based Mylan, which had opposed FDA's decision to allow approval to Ranbaxy's generic version of Lipitor.
Drugmaker Aurobindo Pharma on Monday said it has entered into licensing and supply agreements with London-based pharmaceutical giant AstraZeneca to supply several solid dosage and sterile products for emerging markets.
In the clearest indication from the European Commission yet that a resolution to the ongoing dispute between New Delhi and Brussels regarding generic drug seizures had been reached, a senior EC official told reporters on Wednesday that the EU was "open to changing" the offending regulation.
Already having a deal with GlaxoSmithKline for marketing its products in various emerging markets, Dr Reddy's Laboratories had this week inked an agreement to buy the latter's oral penicillin manufacturing facility at Tennessee in the United States.
The company has sought the United States Food and Drug Administration (FDA)'s approval to market a generic version of Tamiflu (oseltamivir phosphate), said Gilead Sciences, the US company that owns the Tamiflu patent. Natco officials declined to comment on the development.
India may formally approach the World Trade Organisation's dispute panel against the European Union following the seizure of low-cost generic medicine consignments in European ports meant for other developing countries. The two parties have failed to reach an amicable solution during the consultation process.
Pond's, Parle-G, Cadbury, Asian Paints and Amul have captured the changing face of India through the seven decades
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
Merck arm sues Sun over cancer drugSchering Corporation, part of multinational pharma company Merck & Co, and London-based Cancer Research Technology Ltd have sued Sun Pharmaceutical for allegedly infringing patent rights on the world's largest selling brain cancer drug, Temodar.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances